{"article_title": "A Market-Based Alternative To The $750 Pill", "article_keywords": ["alternative", "750", "marketbased", "pill"], "article_url": "http://www.forbes.com/sites/johngoodman/2015/09/25/a-market-based-alternative-to-the-750-pill/", "article_text": "", "article_metadata": {"description": "You probably saw the headlines. Daraprim is a small, white tablet that looks a lot like Aspirin. It was created 62 year ago and treats a parasitic infection called toxoplasmosis. Until recently is sold for $13.50. But then Turing Pharmaceuticals acquired the only company that manufacturers the drug and it [...]", "author": "John C. Goodman", "og": {"site_name": "Forbes", "description": "You probably saw the headlines. Daraprim is a small, white tablet that looks a lot like Aspirin. It was created 62 year ago and treats a parasitic infection called toxoplasmosis. Until recently is sold for $13.50. But then Turing Pharmaceuticals acquired the only company that manufacturers the drug and it [...]", "title": "A Market-Based Alternative To The $750 Pill", "url": "http://www.forbes.com/sites/johngoodman/2015/09/25/a-market-based-alternative-to-the-750-pill/", "image": "http://i.forbesimg.com/media/assets/forbes_1200x1200.jpg", "updated_time": "2015-09-25T08:40:11-04:00", "type": "article"}, "twitter": {"description": "You probably saw the headlines. Daraprim is a small, white tablet that looks a lot like Aspirin. It was created 62 year ago and treats a parasitic infection called toxoplasmosis. Until recently is sold for $13.50. But then Turing Pharmaceuticals acquired the only company that manufacturers the drug and it [...]", "creator": "@@DrJohnCGoodman", "image": "http://i.forbesimg.com/media/assets/forbes_1200x1200.jpg", "title": "A Market-Based Alternative To The $750 Pill", "site": "@forbes", "card": "summary_large_image"}, "apple-itunes-app": "app-id=588647136", "fb": {"app_id": 123694841080850}, "keywords": "Healthcare  Fiscal,OpEd,Healthcare &amp; Fiscal,Op/Ed", "article": {"publisher": "https://www.facebook.com/forbes", "author": "http://www.facebook.com/https://www.facebook.com/profile.php?id=100004450938643&fref=ts", "section_url": "http://www.forbes.com/opinion", "section": "Opinion", "modified": "2015-09-25", "published": "2015-09-25", "id": "blogAndPostId/blog/post/2356-3091"}, "news_keywords": "Healthcare  Fiscal,OpEd,Healthcare &amp; Fiscal,Op/Ed", "viewport": "width=device-width,initial-scale=1,maximum-scale=1,user-scalable=no", "prerender-status-code": "{{meta.code}}"}, "article_summary": ""}